Bioresorbable Coronary Scaffolds Market Trends

Growth Drivers

• Investments in product-related R&D: Both public and private investors are showing interest in upgrading the pipeline of the bioresorbable coronary scaffolds market, creating new business opportunities for global pioneers. For instance, the National Institute of Health (NIH) invested in research in this category in 2024, which was dedicated to polymer-based scaffold innovations. Similarly, the Invest India report in September 2025 depicts that USD 3.39 billion Value of medical devices exported in 2022-23, increased from USD 2.923 billion in 2021-22. These efforts to improve the functionality and cost-effectiveness of products available in this sector are also helping associated companies widen their consumer base.
• Tech-based innovations in intervention and production: The integration of advanced technologies in product designing and manufacturing has significantly improved the output in both quality and scalability in the bioresorbable coronary scaffolds market. Particularly, the current trend of factory automation in every industry, specifically in healthcare, is elevating the approach and quantification of produced goods. Additionally, investments in this aspect from several organizations are empowering parallel developments and production capacity in this sector.
• Rising prevalence of coronary artery disease: The expanding patient pool with coronary artery disease, especially among young adults seeks long term solutions, is a key driver. According to the British Heart Foundation report in August 2025, 640 million people are affected by cardiovascular disease across the world. This is the leading cause of deaths and ensures a steady flow of candidates for PCI. This large growing population creates a sustained demand for advanced treatment options such as bioresorbable coronary scaffolds.

Percentage of Angina in Adults with Age Above 18

Source: CDC September 2025

Challenges

• Economic hurdles in compliance and insurance: The pricing competency in the bioresorbable Coronary Scaffolds market is highly prone to be hindered by regulatory and reimbursement volatilities. In this regard, the Centers for Medicare & Medicaid Services revealed that the scaffold procedures performed across the U.S. were covered by Medicare till 2024. This reflects the gap in accessibility in this field. Additionally, the extended timeline for MDR clearance in Europe caused to the launch budget in 2024. The delay & financial losses in attaining authorized approval and the shortage of adequate financial support cumulatively raise the cost of the final product, making it less accessible for consumers.
• Physician training and adoption issues: Successful B implantation involves having a particular technique and training to prevent complications such as scaffold thrombosis. Overcoming the established clinical preference for familiar DES poses a significant commercial issue. The manufacturers need to spend significantly on physician education and proctoring programs, which are expensive and grow slowly. This retards adoption rates and extends the time to gain a return on investment since physicians remain cautious without extensive real-world data and experience with the new technology.